Ouabain attenuates cardiotoxicity induced by other cardiac steroids. 2010

M Nesher, and U Shpolansky, and N Viola, and M Dvela, and N Buzaglo, and H Cohen Ben-Ami, and H Rosen, and D Lichtstein
Department of Medical Neurobiology, Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel.

OBJECTIVE All cardiac steroids have a similar structure, bind to and inhibit the ubiquitous transmembrane protein Na(+), K(+)-ATPase and increase the force of contraction of heart muscle. However, there are diverse biological responses to different cardiac steroids both at the cellular and at the molecular level. Moreover, we have recently shown that ouabain inhibits digoxin- and bufalin-induced changes in membrane traffic. The present study was designed to test the hypothesis that ouabain also has an inhibitory effect on cardiotoxicity induced by other cardiac steroids. METHODS The hypothesis was tested in isolated heart muscle preparations and in an in vivo model of cardiotoxicity in guinea pigs. RESULTS Ouabain at a low dose attenuated the toxicity induced by bufalin and digoxin in heart muscle preparations. In addition, ouabain at the low dose (91 ng.kg(-1).h(-1)), but not at a higher dose (182 ng.kg(-1).h(-1)), delayed the development of digoxin-induced (500 microg.kg(-1).h(-1)) cardiotoxicity in anaesthetized guinea pigs, as manifested by delayed arrhythmia and terminal ventricular fibrillation, as well as a reduced heart rate. In addition, as observed with ouabain, the phosphoinositide 3-kinase inhibitor wortmannin (100 microg.kg(-1).h(-1)) delayed the digoxin-induced arrhythmia in anaesthetized guinea pigs. CONCLUSIONS The present study demonstrates the inhibitory effect, probably through signal transduction pathways, of ouabain on digoxin- and bufalin-induced cardiotoxicity in guinea pigs. Further understanding of this phenomenon could be beneficial for increasing the therapeutic window for cardiac steroids in the treatment of chronic heart failure.

UI MeSH Term Description Entries
D008297 Male Males
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D010042 Ouabain A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE. Acocantherin,G-Strophanthin,Acolongifloroside K,G Strophanthin
D002018 Bufanolides Cyclopentanophenanthrenes with a 6-membered lactone ring attached at the 17-position and SUGARS attached at the 3-position. They are found in BUFONIDAE and often possess cardiotonic properties. Bufadienolides
D002316 Cardiotonic Agents Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). Cardiac Stimulant,Cardiac Stimulants,Cardioprotective Agent,Cardioprotective Agents,Cardiotonic,Cardiotonic Agent,Cardiotonic Drug,Inotropic Agents, Positive Cardiac,Myocardial Stimulant,Myocardial Stimulants,Cardiotonic Drugs,Cardiotonics,Agent, Cardioprotective,Agent, Cardiotonic,Drug, Cardiotonic,Stimulant, Cardiac,Stimulant, Myocardial
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D000077191 Wortmannin An androstadiene metabolite produced by the fungi PENICILLIUM funiculosum that inhibits PHOSPHATIDYLINOSITOL-3-KINASES and alloantigen-specific activation of T-LYMPHOCYTES in human tumor cell lines. It is widely used in CELL BIOLOGY research and has broad therapeutic potential. MS 54,MS-54,MS54

Related Publications

M Nesher, and U Shpolansky, and N Viola, and M Dvela, and N Buzaglo, and H Cohen Ben-Ami, and H Rosen, and D Lichtstein
July 2023, Free radical biology & medicine,
M Nesher, and U Shpolansky, and N Viola, and M Dvela, and N Buzaglo, and H Cohen Ben-Ami, and H Rosen, and D Lichtstein
January 2015, International journal of clinical and experimental medicine,
M Nesher, and U Shpolansky, and N Viola, and M Dvela, and N Buzaglo, and H Cohen Ben-Ami, and H Rosen, and D Lichtstein
December 1994, Pharmacology,
M Nesher, and U Shpolansky, and N Viola, and M Dvela, and N Buzaglo, and H Cohen Ben-Ami, and H Rosen, and D Lichtstein
November 1966, The Journal of pharmacology and experimental therapeutics,
M Nesher, and U Shpolansky, and N Viola, and M Dvela, and N Buzaglo, and H Cohen Ben-Ami, and H Rosen, and D Lichtstein
January 2019, Evidence-based complementary and alternative medicine : eCAM,
M Nesher, and U Shpolansky, and N Viola, and M Dvela, and N Buzaglo, and H Cohen Ben-Ami, and H Rosen, and D Lichtstein
May 2012, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie,
M Nesher, and U Shpolansky, and N Viola, and M Dvela, and N Buzaglo, and H Cohen Ben-Ami, and H Rosen, and D Lichtstein
March 2021, Human & experimental toxicology,
M Nesher, and U Shpolansky, and N Viola, and M Dvela, and N Buzaglo, and H Cohen Ben-Ami, and H Rosen, and D Lichtstein
October 2023, Toxicology research,
M Nesher, and U Shpolansky, and N Viola, and M Dvela, and N Buzaglo, and H Cohen Ben-Ami, and H Rosen, and D Lichtstein
December 2017, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
M Nesher, and U Shpolansky, and N Viola, and M Dvela, and N Buzaglo, and H Cohen Ben-Ami, and H Rosen, and D Lichtstein
January 2022, Chinese herbal medicines,
Copied contents to your clipboard!